AbCellera Biologics (ABCL) to Release Quarterly Earnings on Thursday

AbCellera Biologics (NASDAQ:ABCL) is projected to post its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect AbCellera Biologics to post earnings of ($0.17) per share and revenue of $6.3330 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

AbCellera Biologics (NASDAQ:ABCL) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. The firm had revenue of $17.08 million for the quarter, compared to the consensus estimate of $7.55 million. AbCellera Biologics had a negative return on equity of 16.17% and a negative net margin of 511.88%. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Stock Performance

NASDAQ:ABCL opened at $5.37 on Tuesday. AbCellera Biologics has a 1 year low of $1.89 and a 1 year high of $6.51. The stock has a fifty day moving average price of $5.08 and a two-hundred day moving average price of $3.95. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -9.76 and a beta of 0.70.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Lantern Wealth Advisors LLC acquired a new stake in shares of AbCellera Biologics during the 2nd quarter worth about $51,000. Invesco Ltd. lifted its stake in shares of AbCellera Biologics by 114.6% during the 1st quarter. Invesco Ltd. now owns 24,146 shares of the company’s stock worth $54,000 after purchasing an additional 12,893 shares during the period. Raymond James Financial Inc. boosted its holdings in shares of AbCellera Biologics by 17.0% during the second quarter. Raymond James Financial Inc. now owns 28,049 shares of the company’s stock worth $96,000 after purchasing an additional 4,070 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of AbCellera Biologics in the second quarter valued at $130,000. Finally, Creative Planning increased its stake in AbCellera Biologics by 6.9% in the second quarter. Creative Planning now owns 41,003 shares of the company’s stock valued at $141,000 after purchasing an additional 2,656 shares during the last quarter. Institutional investors and hedge funds own 61.42% of the company’s stock.

Wall Street Analyst Weigh In

ABCL has been the topic of a number of research analyst reports. Wall Street Zen raised shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Stifel Nicolaus decreased their price target on AbCellera Biologics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Leerink Partners began coverage on AbCellera Biologics in a research note on Monday, July 7th. They issued an “outperform” rating and a $5.00 price objective for the company. KeyCorp boosted their target price on AbCellera Biologics from $5.00 to $10.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. Finally, Leerink Partnrs raised shares of AbCellera Biologics to a “strong-buy” rating in a research note on Monday, July 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.00.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.